Recent Comments

    Archives

    Categories

    Cell surface protein may offer big target in treating high-risk childhood cancers

    Original @ Medical Xpress – latest medical and health news stories Oncology researchers studying high-risk children’s cancers have identified a protein that offers a likely target for immunotherapy—harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells. [...]

    Cell surface protein may offer big target in treating high-risk childhood cancers

    Original @ Medical Xpress – latest medical and health news stories Oncology researchers studying high-risk children’s cancers have identified a protein that offers a likely target for immunotherapy—harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells. [...]

    Cancer patients struggle with key aspects of clinical trial methodology

    Original @ Medical Xpress – latest medical and health news stories Clinical trials are fundamental to the development of new treatments for cancer, yet the annual accrual to cancer clinical trials worldwide is low, estimated at three to five percent. A nationwide study in Ireland, the preliminary results of which are … [...]

    DNA sequencing could open up new drug indications for patients with rare cancers

    Original @ Medical Xpress – latest medical and health news stories Thanks to DNA sequencing, patients with rare cancers for which no standard treatment is available could receive existing therapies that work in patients treated for different cancers, but who carry the same genetic mutations. The first results of a mul… [...]

    No difference in toxicity for 6-, 2-fraction HDR in prostate cancer

    Original @ Medical Xpress – latest medical and health news stories (HealthDay)—For men with prostate cancer there is no difference in acute genitourinary or sexual dysfunction between 6- and 2-fraction high-dose-rate (HDR) brachytherapy monotherapy, according to a study published online Aug. 29 in the Journal of Medical Imaging and Radiation Oncology. [...]

    No difference in toxicity for 6-, 2-fraction HDR in prostate cancer

    Original @ Medical Xpress – latest medical and health news stories (HealthDay)—For men with prostate cancer there is no difference in acute genitourinary or sexual dysfunction between 6- and 2-fraction high-dose-rate (HDR) brachytherapy monotherapy, according to a study published online Aug. 29 in the Journal of Medical Imaging and Radiation Oncology. [...]

    Helping cancer survivors return to work

    Original @ Medical Xpress – latest medical and health news stories A new Psycho-Oncology analysis of published studies indicates that there are various employer-related factors that can help or hinder cancer survivors as they attempt to go back to work. [...]

    Liver cancer patients can start with lower dose of chemotherapy and live just as long

    Original @ Medical Xpress – latest medical and health news stories Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not affect how long they live when compared to patients who… [...]

    How to implement Advance Care Planning for patients

    Original @ Medical Xpress – latest medical and health news stories Emeritus Professor Sheila Payne from the International Observatory on End of Life Care at Lancaster University helped conduct the study commissioned by the European Association for Palliative Care (EAPC) and published in The Lancet Oncology. [...]

    Palliative care makes only limited gains in Africa

    Original @ Medical Xpress – latest medical and health news stories Palliative care has increased in Africa over the past 12 years but only in a small subset of countries, according to a review published today in Lancet Oncology. This research was led by John Y. Rhee, a fourth-year medical student at the Icahn School o… [...]